GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities class action lawsuit for allegedly failing to disclose material information about its acquisition performance. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, and disclosed a $31.2 million impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% following the May 4, 2026 announcement, with the company lowering full-year revenue guidance from $540-$550 million to $475-$490 million.